RS64258B1 - Heteroarilfenoksi benzamid ligandi kapa opioida - Google Patents

Heteroarilfenoksi benzamid ligandi kapa opioida

Info

Publication number
RS64258B1
RS64258B1 RS20230453A RSP20230453A RS64258B1 RS 64258 B1 RS64258 B1 RS 64258B1 RS 20230453 A RS20230453 A RS 20230453A RS P20230453 A RSP20230453 A RS P20230453A RS 64258 B1 RS64258 B1 RS 64258B1
Authority
RS
Serbia
Prior art keywords
methyl
pyrazol
phenoxy
pyrrolidin
benzamide
Prior art date
Application number
RS20230453A
Other languages
English (en)
Serbian (sr)
Inventor
Kapildev Kashmirilal Arora
Michael Aaron Brodney
Matthew Francis Dunn
Michael Eric Green
Natasha Mariam Kablaoui
Gregory Wayne Kauffman
Scot Richard Mente
Justin Ian Montgomery
Danica Antonia Rankic
Bruce Nelsen Rogers
Patrick Robert Verhoest
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of RS64258B1 publication Critical patent/RS64258B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18One oxygen or sulfur atom
    • C07D231/20One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20230453A 2016-11-28 2017-11-27 Heteroarilfenoksi benzamid ligandi kapa opioida RS64258B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662426980P 2016-11-28 2016-11-28
US201762576435P 2017-10-24 2017-10-24
US201762585016P 2017-11-13 2017-11-13
EP17818281.2A EP3544972B8 (en) 2016-11-28 2017-11-27 Heteroarylphenoxy benzamide kappa opioid ligands
PCT/IB2017/057418 WO2018096510A1 (en) 2016-11-28 2017-11-27 Heteroarylphenoxy benzamide kappa opioid ligands

Publications (1)

Publication Number Publication Date
RS64258B1 true RS64258B1 (sr) 2023-07-31

Family

ID=60782279

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230453A RS64258B1 (sr) 2016-11-28 2017-11-27 Heteroarilfenoksi benzamid ligandi kapa opioida

Country Status (18)

Country Link
US (1) US10316021B2 (cg-RX-API-DMAC7.html)
EP (1) EP3544972B8 (cg-RX-API-DMAC7.html)
JP (1) JP7051853B2 (cg-RX-API-DMAC7.html)
CN (1) CN110234638B (cg-RX-API-DMAC7.html)
AU (1) AU2017365123B2 (cg-RX-API-DMAC7.html)
DK (1) DK3544972T3 (cg-RX-API-DMAC7.html)
ES (1) ES2947293T3 (cg-RX-API-DMAC7.html)
FI (1) FI3544972T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230518T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061945T2 (cg-RX-API-DMAC7.html)
IL (1) IL266962B (cg-RX-API-DMAC7.html)
MX (1) MX389806B (cg-RX-API-DMAC7.html)
PH (1) PH12019501172A1 (cg-RX-API-DMAC7.html)
PL (1) PL3544972T3 (cg-RX-API-DMAC7.html)
PT (1) PT3544972T (cg-RX-API-DMAC7.html)
RS (1) RS64258B1 (cg-RX-API-DMAC7.html)
TW (1) TWI720272B (cg-RX-API-DMAC7.html)
WO (1) WO2018096510A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018154118A2 (en) * 2017-02-24 2018-08-30 Reinmueller Viktoria Novel aromatic compounds
EP3585485A2 (en) 2017-02-24 2020-01-01 Xeniopro GmbH Aromatic compounds which enhance notch signaling, for use in therapy
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN111233768B (zh) * 2020-03-18 2021-08-03 徐州圣元化工有限公司 一种3-(二氟甲基)-1-甲基-1h-吡唑-4-羧酸乙酯的制备方法
MX2021013934A (es) * 2020-04-05 2021-12-15 Pfizer Compuestos y metodos para el tratamiento de covid-19.
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN119156202A (zh) 2022-03-07 2024-12-17 杨森制药公司 包含阿替卡普兰的组合物
JP2025508071A (ja) * 2022-03-07 2025-03-21 ヤンセン ファーマシューティカルズ,インコーポレーテッド 純粋な形態の結晶質アチカプラント
JP2025508051A (ja) 2022-03-07 2025-03-21 ヤンセン ファーマシューティカルズ,インコーポレーテッド 大うつ病性障害の治療に使用するためのアチカプラントの多形形態
WO2024079733A1 (en) * 2022-10-12 2024-04-18 Adama Makhteshim Ltd. Process for the preparation of aminopyridazine derivatives

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2000159747A (ja) * 1998-09-21 2000-06-13 Takeda Chem Ind Ltd 新規チオ―ル誘導体、その製造法および用途
WO2000017162A1 (en) 1998-09-21 2000-03-30 Takeda Chemical Industries, Ltd. Novel thiol derivatives, process for producing the same and utilization thereof
IT1303737B1 (it) 1998-11-11 2001-02-23 Smithkline Beecham Spa Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1.
JP4646628B2 (ja) 2002-09-19 2011-03-09 イーライ リリー アンド カンパニー オピオイド受容体アンタゴニストとしてのジアリールエーテル類
US7365209B2 (en) 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
CA2513791A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company Opioid receptor antagonists
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
AU2005268030B2 (en) 2004-08-06 2009-02-19 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
KR100922093B1 (ko) 2005-02-18 2009-10-16 닛뽕소다 가부시키가이샤 유기 무기 복합체
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
CA2646899C (en) 2006-04-04 2014-05-06 Holger Lars Hermann Use of compositions containing kappa-opioid receptor antagonists for the treatment of dissociative disorders
SI2252581T1 (sl) 2008-01-22 2012-09-28 Lilly Co Eli Antagonist kappa selektivnega opioidnega receptorja
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
CR11559A (es) 2008-03-25 2010-10-20 Lilly Co Eli Antagonista del receptor opioide selectivo kappa
US8048895B2 (en) 2008-04-18 2011-11-01 Research Triangle Institute Kappa opioid receptor ligands
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CA2746943A1 (en) 2008-12-18 2010-07-15 Boehringer Ingelheim International Gmbh Serotonin 5-ht2b receptor inhibitors
HN2010001319A (es) 2009-01-26 2013-01-15 Lilly Co Eli Antagonista del receptor opioide selectivo kappa
WO2013059648A1 (en) 2011-10-21 2013-04-25 Neurotherapeutics Pharma, Inc. 2,3,5 trisubstituted aryl and heteroaryl amino derivatives, compositions, and methods of use
JP2015531382A (ja) 2012-10-02 2015-11-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ピロリジン
WO2015109080A1 (en) 2014-01-15 2015-07-23 Research Triangle Institute Kappa-opioid receptor selective opioid receptor antagonists
US10118896B2 (en) 2014-11-26 2018-11-06 University Of Kansas Antagonists of the kappa opioid receptor

Also Published As

Publication number Publication date
IL266962A (en) 2019-07-31
MX389806B (es) 2025-03-20
NZ754862A (en) 2024-11-29
CN110234638A (zh) 2019-09-13
HRP20230518T1 (hr) 2023-08-04
EP3544972A1 (en) 2019-10-02
CN110234638B (zh) 2022-10-21
JP7051853B2 (ja) 2022-04-11
PT3544972T (pt) 2023-06-20
US10316021B2 (en) 2019-06-11
CA3045242A1 (en) 2018-05-31
MX2019006220A (es) 2019-10-07
HUE061945T2 (hu) 2023-09-28
EP3544972B1 (en) 2023-04-26
FI3544972T3 (fi) 2023-06-02
AU2017365123A1 (en) 2019-07-11
IL266962B (en) 2022-02-01
DK3544972T3 (da) 2023-05-30
EP3544972B8 (en) 2023-06-07
WO2018096510A1 (en) 2018-05-31
TW201831460A (zh) 2018-09-01
ES2947293T3 (es) 2023-08-04
US20180148432A1 (en) 2018-05-31
TWI720272B (zh) 2021-03-01
PH12019501172A1 (en) 2019-12-11
AU2017365123B2 (en) 2022-02-17
JP2019535799A (ja) 2019-12-12
PL3544972T3 (pl) 2023-07-24

Similar Documents

Publication Publication Date Title
AU2017365123B2 (en) Heteroarylphenoxy benzamide kappa opioid ligands
KR102161364B1 (ko) LRRK2 억제제로서 이미다조[4,5-c]퀴놀린 및 이미다조[4,5-c][1,5]나프티리딘 유도체
US9388192B2 (en) Benzimidazole derivatives as Kinase Inhibitors
JP2015157826A (ja) 内臓痛を治療するためのインドール化合物および方法
US11390623B2 (en) 6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands
EA030085B1 (ru) 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
CA3045816A1 (en) Oga inhibitor compounds
US20080081833A1 (en) Novel Pyrazole Derivatives And Their Use As Modulators Of Nicotinic Acetylcholine Receptors
US20170066753A1 (en) Oxadiazine compounds and methods of use thereof
CN104337812B (zh) 取代的杂芳基化合物及其使用方法和用途
TWI675826B (zh) 環狀經取代之咪唑并[4,5-c]喹啉衍生物
US20210300943A1 (en) Oga inhibitor compounds
CA3045242C (en) Heteroarylphenoxy benzamide kappa opioid ligands
HK40014240B (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
HK40014240A (en) Heteroarylphenoxy benzamide kappa opioid ligands
US20070197609A1 (en) Salts of inducible nitric oxide synthase dimerization inhibitors
JP7713954B2 (ja) 核内受容体に対して活性な化合物
TW202014191A (zh) 具有選擇性bace1抑制活性的四氫哌喃并衍生物
HK40021310A (en) Cyclic substituted imidazo[4,5-c]quinoline derivatives